Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-14 January 2026

Veterinary medicines European public assessment report (EPAR): Lotilaner / Milbemycin Elanco, lotilaner,milbemycin oxime, Status: Opinion

Referral: Oxbryta, voxelotor Article 20 procedures European Commission final decision, 16/10/2025, 09/12/2025, 16/01/2026

Human medicines European public assessment report (EPAR): Victoza, liraglutide, Date of authorisation: 30/06/2009, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Ifirmacombi, irbesartan,hydrochlorothiazide, Date of authorisation: 04/03/2011, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Irbesartan/Hydrochlorothiazide Teva, irbesartan,hydrochlorothiazide, Date of authorisation: 26/11/2009, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 19, Status: Authorised

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12 - 15 January 2026